Metabolic research
Cagrilintide
Cagrilintide is a long-acting amylin analogue, a lipidated peptide distinct from GLP-1 receptor agonists. VaultLabs supplies it as standalone 5 mg and 10 mg lyophilized vials for in vitro laboratory work. It is not retatrutide, not the cagrilintide portion of the RETA/CAG blend, and not an approved medicine.
Research use only. For in vitro research use only. Not for human or animal consumption. Not for human consumption, medical use, or personal application.
Reviewed by VaultLabs Research Editorial Desk · Last updated 2026-10-20
Key facts
- Amylin analogue, not a GLP-1, GIP or glucagon receptor agonist.
- CAS 1415456-99-3. Formula C194H312N54O59S2. Molecular weight 4409.07 g/mol.
- Catalogue fills are 5 mg and 10 mg. Each fill has its own lot.
- RETA/CAG is a different product: retatrutide 12.5 mg plus cagrilintide 2.5 mg in one vial.
- Published clinical papers describe other sponsors' studies. They are not a description of this vial.
- Supplied for laboratory research. Not for human use.
- Chemical name
- Cagrilintide
- Common synonyms
- Cagri, long-acting amylin analogue
- CAS number
- 1415456-99-3
- Molecular formula
- C194H312N54O59S2
- Molecular weight
- 4409.07 g/mol
- Catalog strength
- 5 mg and 10 mg vials
What Cagrilintide is
Cagrilintide is the catalogue name for the long-acting amylin analogue with CAS 1415456-99-3. Public records describe a 38-residue peptide with a fatty diacid and a disulfide. That is a different molecule from retatrutide (CAS 2381089-83-2), which is the GLP-3 RT line. Ordering one when the protocol names the other is a receiving error, not a strength choice.
Cagrilintide is a long-acting amylin analogue, a lipidated peptide distinct from GLP-1 receptor agonists. VaultLabs supplies it as standalone 5 mg and 10 mg lyophilized vials for in vitro laboratory work. It is not retatrutide, not the cagrilintide portion of the RETA/CAG blend, and not an approved medicine.
How VaultLabs catalogues it
VaultLabs lists two standalone fills, Cagrilintide 5mg and 10 mg, on one product page with a strength selector. The 5 mg URL is the commercial page. A 5 mg certificate does not release a 10 mg vial. The RETA/CAG 15mg blend contains 2.5 mg of cagrilintide beside 12.5 mg of retatrutide and keeps a separate lot. Use the retatrutide procurement page only when the single-sequence GLP-3 RT line is the material you meant.
Searchers type cagri, cagrilintide and sometimes reta/cag as if they were one SKU. They are not. Write the catalogue string and the fill on the purchase order. The compound monograph at Cagrilintide holds the registry numbers. This page holds the UAE ordering facts: price in AED, 24-hour dispatch, and which neighbouring vial must not be substituted.
Lots and receiving
Each sealed unit carries its own lot number. The current catalogue certificate for that lot is published on the batch page and states purity of at least 99.8 percent on the same VaultLabs template used for the rest of the lyophilized catalogue. A certificate for one fill does not qualify another fill. A certificate for a blend does not qualify a single-sequence vial that happens to share part of a name. Do not copy a purity figure from a different product, from a photograph of another vial, or from a paper into the receiving file. Match the printed name, the nominal mass and the lot number on the vial to the published record. If those three do not agree, hold the unit and ask for the document that belongs to that unit before it leaves quarantine. Enter the printed lot at batch verification.
Storage and research-use boundary
Keep the sealed lyophilized vial at 2 to 8 degrees Celsius, protected from light and from moisture, until it is opened under the laboratory's own procedure. Allow the closed vial to reach room temperature before the seal is broken, so water from humid coastal air does not condense on the dry cake. Bacteriostatic water and sterile water are separate catalogue lines. They are not packed inside the peptide box, because the receiving laboratory chooses the medium in its own procedure. VaultLabs does not publish a preparation method on this page. After the seal is opened, solution age, container and freeze cycles are controlled by the laboratory, not by the catalogue page.
The material is supplied for in vitro laboratory research only. It is not for human or animal consumption. It is not an approved medicine, not a finished cosmetic, and not a personal-use item. Papers cited on the compound monograph describe other people's experiments. Those papers are not a description of what this vial will do, and they are not instructions for any person or animal. A buyer who needs a registered medicine should use a licensed pharmacy channel. This page exists so a procurement officer in the UAE can identify the catalogue line, the fill, the price band and the paperwork before raising an order.
Research interest areas
Amylin analogue, not a GLP-1, GIP or glucagon receptor agonist.
CAS 1415456-99-3. Formula C194H312N54O59S2. Molecular weight 4409.07 g/mol.
Catalogue fills are 5 mg and 10 mg. Each fill has its own lot.
RETA/CAG is a different product: retatrutide 12.5 mg plus cagrilintide 2.5 mg in one vial.
Storage information
2–8 °C (lyophilized, sealed)
2–8 °C sealed lyophilized storage, protected from light and humidity.
Stability notes
Keep the sealed lyophilized vial at 2 to 8 degrees Celsius, protected from light and from moisture, until it is opened under the laboratory's own procedure. Allow the closed vial to reach room temperature before the seal is broken, so water from humid coastal air does not condense on the dry cake. Bacteriostatic water and sterile water are separate catalogue lines. They are not packed inside the peptide box, because the receiving laboratory chooses the medium in its own procedure. VaultLabs does not publish a preparation method on this page. After the seal is opened, solution age, container and freeze cycles are controlled by the laboratory, not by the catalogue page.
Selected literature
Named papers behind the statements on this page. Each entry resolves on PubMed and through its DOI, so you can read the source rather than take our summary of it. Inclusion describes the research record and is not a claim about this material’s suitability for any use.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, et al. · The Lancet · 2021
Identity context for the amylin analogue. The paper is not a description of the VaultLabs vial and is not a use instruction.
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, et al. · The Lancet · 2023
Shows why a cagrilintide-plus-another-peptide combination is a different material from cagrilintide alone. Literature context only.
Databases and verification
Registry and database entries for independent identity checks. These are standing searches rather than fixed records, so they stay current as new work is indexed.
- Cagrilintide on PubChem — PubChem
- Cagrilintide literature search — PubMed
- CAS Common Chemistry — 1415456-99-3 — CAS